Interested in the biotech industry? For ideas of where to start looking, we ran a screen on the stocks of the biotech industry for those with "Buy" ratings from Deutsche Bank.
Analysts at Deutsche Bank believe these stocks will soon outperform - what do you think?
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.
We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.
Do you think these stocks will outperform like Deutsche Bank expects? Use this list as a starting point for your own analysis.
List sorted by ratings date.
1. BioMarin Pharmaceutical Inc. (BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap of $4.07B. On 09/28/2011, Deutsche Bank had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 6.77% (equivalent to 9.6 days of average volume). The stock has had a couple of great days, gaining 5.73% over the last week.
2. Amyris, Inc. (AMRS): An integrated renewable products company, offers renewable compounds for a variety of markets. Market cap of $531.11M. On 09/16/2011, Deutsche Bank had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 16.17% (equivalent to 21.41 days of average volume). The stock has lost 58.04% over the last year.
3. Biogen Idec Inc. (BIIB): Develops, manufactures and markets therapeutics in the areas of neurology, immunology, hemophilia and oncology in the United States and internationally. Market cap of $28.0B. On 06/21/2011, Deutsche Bank had a Buy rating on the stock. The stock has gained 72.86% over the last year.
*Data sourced from Yahoo! Finance.